## Understanding the Expanding Ebola Bundibugyo Outbreak in DRC The Democratic Republic of Congo (DRC) is currently facing a serious health crisis: a rapidly expanding outbreak of Ebola disease caused by the Bundibugyo virus (BVD). This severe illness has escalated to a Public Health Emergency of International Concern, signaling its gravity and the need for coordinated global action. The situation has worsened considerably since its initial detection, with the virus spreading across numerous communities and proving challenging to contain amidst complex humanitarian circumstances. As of late August 2026, the outbreak has significantly widened its reach within the DRC. The disease, first identified in May 2026, is now affecting 60 health zones across six of the country's 26 provinces: Bas-Uélé, Haut-Uélé, Ituri, North Kivu, South Kivu, and Tshopo. Ituri remains the epicenter, reporting the highest number of cases, while North Kivu has seen a particularly high case fatality rate. This geographic expansion represents a substantial increase in the outbreak's scale over just a few months. ## What is Bundibugyo Virus Disease (BVD)? Bundibugyo virus disease is a particularly dangerous form of Ebola, belonging to the same family of viruses (Filoviridae) known for causing severe, often fatal, hemorrhagic fever. The Bundibugyo virus is one of several types of *Orthoebolavirus*. It's a zoonotic disease, meaning it originates in animals, with fruit bats strongly suspected to be its natural hosts in the wild. Human infection typically begins through close contact with the blood or other body fluids of infected wild animals, such as bats or non-human primates. Once a human is infected, the virus can then spread rapidly from person to person. This occurs through direct contact with the blood, secretions, organs, or other bodily fluids of infected individuals, or through touching surfaces and materials contaminated with these fluids. The risk of transmission is especially high in healthcare settings if proper infection control measures are not rigorously followed, and during traditional burial practices that involve direct contact with the deceased. The incubation period for BVD, the time from infection to the appearance of symptoms, can range from two to 21 days. Crucially, infected individuals are not contagious until they start showing symptoms. Early signs of the disease are often non-specific, resembling common illnesses like malaria or the flu, making early diagnosis difficult. These initial symptoms include fever, extreme fatigue, muscle pain, headaches, and a sore throat. As the disease progresses, it can lead to severe gastrointestinal issues, organ failure, and in some cases, internal and external bleeding. ## The Current Outbreak: A Growing Challenge The sheer scale of the current outbreak in the DRC is alarming. By late August 2026, a total of 5,794 confirmed cases had been reported within the Democratic Republic of Congo alone, resulting in 2,786 deaths. This translates to a crude case fatality ratio (CFR) of 48.1%, meaning nearly half of all confirmed cases have been fatal. When considering cases diagnosed in DRC but treated abroad, along with those in neighboring Uganda and France, the cumulative confirmed cases reached 5,815 with 2,788 deaths. While Uganda and France have since completed their 42-day enhanced monitoring periods, the intense transmission within the DRC highlights the ongoing severity. This high mortality rate underscores the critical challenges in detecting cases early, providing timely and effective clinical care, and stopping the virus from spreading. Delays in recognizing BVD can lead to further transmission within households, communities, and even healthcare facilities, compounding the problem. Despite expanded surveillance and improved diagnostic capabilities contributing to the higher case numbers, the sustained rise undeniably points to persistent transmission and a significant expansion of the disease. ## Why is Containing This Outbreak So Difficult? The fight against BVD in the DRC is exceptionally complex, deeply intertwined with the country's ongoing humanitarian crisis. The outbreak is unfolding in regions plagued by persistent conflict, armed violence, and large-scale displacement of populations. More than 26 million people in the DRC face severe food insecurity, and an estimated one million internally displaced persons (IDPs) reside in Ituri Province alone—the current epicenter of the BVD outbreak. This environment of insecurity and displacement creates immense obstacles for public health teams. Access to healthcare and essential services is disrupted, making it difficult for responders to reach affected areas and for sick individuals to seek help. Surveillance, case investigation, and contact tracing — fundamental tools for outbreak control — are severely hampered. Overcrowded conditions in informal settlements, mining communities, and IDP sites, coupled with limited access to clean water, sanitation, and hygiene (WASH) services, further accelerate transmission and hinder effective prevention measures. These factors make it incredibly challenging to implement consistent response strategies and reach all vulnerable populations. ## International Alarm and Regional Risks Given the rapid spread and the difficulties in containment, the World Health Organization (WHO) has declared the BVD outbreak in the DRC a Public Health Emergency of International Concern (PHEIC). This declaration signifies a serious public health risk that requires a coordinated international response. While France and Uganda have successfully completed their monitoring periods, the continuous, intense transmission within the DRC maintains a high risk of the virus spreading across international borders. Measures like health screening at airports, ports, and official land crossings are in place, but the reality of movement through informal border routes presents an ongoing vulnerability for the virus to be exported, imported, and transmitted further. Therefore, robust cross-border collaboration, sustained surveillance, and strong preparedness plans are vital to prevent wider regional spread. The WHO has assessed the risk within the DRC as very high due to active transmission and expansion. For countries sharing land borders, such as Uganda, the Central African Republic, and South Sudan, the risk remains high due to significant population mobility, trade, mining activities, and varied health system capacities and readiness levels. These neighboring countries often grapple with their own humanitarian challenges, which could worsen the impact if the virus crosses borders. ## Global and Local Response Efforts In response to this grave challenge, health authorities in the Democratic Republic of Congo, working closely with the WHO and numerous international partners, are implementing extensive public health measures. These efforts encompass disease surveillance, rapid laboratory testing, stringent infection prevention and control (IPC) protocols, and comprehensive clinical care for patients. Community engagement is a cornerstone of the response, vital for building trust and ensuring the acceptance of health interventions, including safe and dignified burial practices that prevent further spread. Furthermore, research and logistics support are critical, along with continuous efforts to mobilize resources and address funding gaps to sustain operations in affected and high-risk areas. A substantial scale-up is underway across all aspects of the response to try and get ahead of the outbreak. On the treatment front, while no specific approved treatments exist for BVD, a clinical trial known as the PARTNERS trial has been initiated in Ituri province, enrolling over 250 confirmed cases to evaluate potential therapies. This trial is crucial for finding effective interventions. ## Hope on the Horizon: Vaccine and Treatment Research Vaccination efforts are also part of the strategy. The Ervebo vaccine, which has proven safe and effective against the Zaire Ebola virus, has been rolled out for healthcare workers in some areas of the DRC, including Kisangani in Tshopo province. However, it's important to note that whether Ervebo offers protection against the Bundibugyo virus in humans is not yet known. Therefore, a clinical trial of the Ervebo vaccine specifically for BVD is critical and is being pursued alongside its broader use. This research will provide vital evidence to guide future vaccination strategies against this particular strain of Ebola. WHO continues to monitor the situation closely and advises against any travel or trade restrictions with the affected countries, emphasizing that such measures can hinder response efforts and negatively impact local economies. Instead, the focus remains on enhancing coordinated outbreak control, strengthening cross-border collaboration, and ensuring ongoing surveillance and preparedness. Rapid detection of cases, accurate testing, and optimized supportive care are key not only to reducing mortality but also to improving community trust and acceptance of essential healthcare services within the response.